Mantle Cell Lymphoma Clinical Trials

53 recruiting

Mantle Cell Lymphoma Trials at a Glance

78 actively recruiting trials for mantle cell lymphoma are listed on ClinicalTrialsFinder across 6 cities in 36 countries. The largest study group is Phase 2 with 47 trials, with the heaviest enrollment activity in Duarte, Houston, and Seattle. Lead sponsors running mantle cell lymphoma studies include City of Hope Medical Center, M.D. Anderson Cancer Center, and Ruijin Hospital.

Browse mantle cell lymphoma trials by phase

Treatments under study

About Mantle Cell Lymphoma Clinical Trials

Looking for clinical trials for Mantle Cell Lymphoma? There are currently 53 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Mantle Cell Lymphoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Mantle Cell Lymphoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 78 trials

Recruiting
Phase 2

A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06)

Relapsed or Refractory Mantle Cell Lymphoma (MCL)
Beijing InnoCare Pharma Tech Co., Ltd.75 enrolled29 locationsNCT07082686
Recruiting
Phase 2

A Study Comparing Rituximab/Bendamustin(RB) Alternating With Rituximab/Bendamustin/Cytarabin(RBAC) With RB Therapy in Elderly Patients With Mentle Cell Lymphoma

Mantle Cell Lymphoma
Kim, Seok Jin90 enrolled1 locationNCT05245656
Recruiting
Phase 2

Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) Patients

Mantle Cell Lymphoma
M.D. Anderson Cancer Center50 enrolled1 locationNCT06263491
Recruiting
Phase 3

A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)

Mantle Cell Lymphoma
BeOne Medicines300 enrolled148 locationsNCT06742996
Recruiting
Phase 1Phase 2

A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

Diffuse Large B Cell LymphomaChronic Lymphocytic LeukemiaNon-Hodgkin Lymphoma+6 more
BeOne Medicines614 enrolled127 locationsNCT05006716
Recruiting
Phase 2

Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma

Chronic Lymphocytic LeukemiaMantle Cell LymphomaRecurrent Chronic Lymphocytic Leukemia+6 more
Fred Hutchinson Cancer Center30 enrolled1 locationNCT06839053
Recruiting

Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax

Mantle Cell LymphomaSudden Cardiac DeathChronic Lymphocytic Leukemia (CLL)+3 more
National Heart, Lung, and Blood Institute (NHLBI)135 enrolled1 locationNCT05724121
Recruiting
Phase 1Phase 2

Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma

Mantle Cell Lymphoma
City of Hope Medical Center28 enrolled4 locationsNCT03523975
Recruiting
Phase 1

Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaRecurrent Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaRecurrent Diffuse Large B-Cell Lymphoma+16 more
City of Hope Medical Center37 enrolled1 locationNCT06859008
Recruiting
Phase 2

Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma

Mantle Cell Lymphoma
University of California, San Francisco30 enrolled3 locationsNCT06252675
Recruiting
Phase 2

Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy

Recurrent Mantle Cell LymphomaRefractory Mantle Cell Lymphoma
National Cancer Institute (NCI)20 enrolled5 locationsNCT07003295
Recruiting
Phase 1Phase 2

Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader

Non-Hodgkin LymphomaMantle Cell LymphomaFollicular Lymphoma+6 more
BeiGene146 enrolled29 locationsNCT05294731
Recruiting
Phase 2

Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients

Mantle Cell Lymphoma
M.D. Anderson Cancer Center30 enrolled1 locationNCT05529069
Recruiting
Phase 1Phase 2

Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma

Diffuse Large B Cell LymphomaHodgkin LymphomaMantle Cell Lymphoma+6 more
New York Medical College20 enrolled1 locationNCT04491370
Recruiting
Phase 3

A Long-term Extension Study of PCI-32765 (Ibrutinib)

Chronic Lymphocytic LeukemiaMantle Cell LymphomaFollicular Lymphoma+1 more
Janssen Research & Development, LLC700 enrolled174 locationsNCT01804686
Recruiting
Phase 3

Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma

Mantle Cell Lymphoma
Alliance for Clinical Trials in Oncology421 enrolled233 locationsNCT05976763
Recruiting
Phase 1

Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma

Recurrent Mantle Cell LymphomaRefractory Mantle Cell Lymphoma
City of Hope Medical Center10 enrolled1 locationNCT06675123
Recruiting
Phase 1

CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies

Diffuse Large B Cell LymphomaHigh-grade B-cell LymphomaMantle Cell Lymphoma+5 more
British Columbia Cancer Agency24 enrolled7 locationsNCT06208735
Recruiting
Phase 2

Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCL

Mantle Cell Lymphoma
H. Lee Moffitt Cancer Center and Research Institute60 enrolled3 locationsNCT06553872
Recruiting
Phase 1Phase 2

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

Diffuse Large B Cell LymphomaHigh-grade B-cell LymphomaChronic Lymphocytic Leukemia+8 more
Vironexis Biotherapeutics Inc.32 enrolled9 locationsNCT06533579